An overview of cord blood stem cell transplantation in Hong Kong
DOI:
https://doi.org/10.20883/medical.e741Keywords:
biobanking, haematopoietic stem cells, American Association of Blood Banks, Association for the Advancement of Blood & Biotherapies, Foundation for the Accreditation of Cellular Therapy, College of American Pathologists, cord blood bank, unrelated haematopoietic stem cell transplantAbstract
Haematopoietic stem cell graft derived from cord blood is standard therapy for several haematological malignancies and other diseases. The study reports cases of public and private (family) cord blood biobanking services and the related hematopoietic stem cell transplantation ever performed in Hong Kong. The published original research papers and review articles from inception to Nov 2022 have been searched for on Pubmed, Microsoft Academic Search, and Google Scholar to identify reports on existing or terminated cord blood biobanking and transplantation service in Hong Kong. Moreover, all data publicly available on the official websites of the local cord blood banks and local mainstream media has been analysed. The public Hong Kong Red Cross Blood Transfusion Service delivers the highest quantity of haematopoietic stem cell transplants. Among the private sector, HealthBaby releases the most cord blood units for clinical use in diseases in both autologous and allogeneic administration, followed by Cordlife HK. Both public and private (family) cord blood biobanks have been and continue to contribute to the Hong Kong cord blood donor registry. However, the growth of the cord blood inventory is detrimental to donor-recipient matching for lifesaving therapy.
Downloads
References
Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-8.
Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2022.
Khaddour K, Hana CK, Mewawalla P. Hematopoietic Stem Cell Transplantation. StatPearls. Treasure Island (FL)2022.
James CCaB. Haemopoietic stem cell transplantation is a curative treatment option with minimal transplant-related complications for patients with severe Glanzmann's thrombasthenia. Clin Med (Lond). 2019;19(34).
Panz-Klapuch M, Spalek A, Duda K, Kopinska A, Wieczorkiewicz-Kabut A, Helbig G. Allogeneic hematopoietic stem cell transplantation for relapsed Bcell acute lymphoblastic leukemia after failure of autologous hematopoietic stem cell transplantation: a retrospective single-center analysis. Pol Arch Intern Med. 2022;132(3).
Khemani K, Katoch D, Krishnamurti L. Curative Therapies for Sickle Cell Disease. Ochsner J. 2019;19(2):131-7.
Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica. 2020;105(12):2716-29.
Xue E, Milano F. Are we underutilizing bone marrow and cord blood? Review of their role and potential in the era of cellular therapies. F1000Res. 2020;9.
Shpall EJ, Rezvani K. Cord blood expansion has arrived. Blood. 2021;138(16):1381-2.
Dumont-Lagace M, Feghaly A, Meunier MC, Finney M, Van't Hof W, Masson Frenet E, et al. UM171 Expansion of Cord Blood Improves Donor Availability and HLA Matching For All Patients, Including Minorities. Transplant Cell Ther. 2022.
Database GCBI. Global Cord Blood Industry Database, 2021. Retrieved on 15 Jun 2022.
Association WMD. Cord blood: the basics. 2022 Jun16.
Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant. 2010;16(11):1541-8.
Foundation PsGtCB. Accreditation Standards Retrieved on 15 Jun 2022.
Joris M, Paulson K, Foley L, Duffy M, Querol S, Gomez S, et al. Worldwide survey on key indicators for public cord blood banking technologies: By the World Marrow Donor Association Cord Blood Working Group. Stem Cells Transl Med. 2021;10(2):222-9.
Association TWMD. NetCord-FACT Standards. Retrieved on 15 Jun 2022.
Therapy FftAoC. Cord Blood Bank Standards. Retrieved on 15 Jun 2022.
Reese EM, Nelson RC, Flegel WA, Byrne KM, Booth GS. Critical Value Reporting in Transfusion Medicine: A Survey of Communication Practices in US Facilities. Am J Clin Pathol. 2017;147(5):492-9.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
Li CK, Shing MM, Chik KW, Tsang KS, Tang NL, Chan PK, et al. Unrelated umbilical cord blood transplantation in children: experience of the Hong Kong Red Cross Blood Transfusion Service. Hong Kong Med J. 2004;10(2):89-95.
Corporation HKSaTP. PUBLIC NOTICE. Retrieved on 27 Jun 2022.
Lopez MC, Lawrence DA. Proficiency testing experience for viable CD34+ stem cell analysis. Transfusion. 2008;48(6):1115-21.
Viswanathan C, Roy A, Damodaran D, Manira AK, Kabra P. Optimization of the inventory size of the public cord blood program--the Indian context. J Assoc Physicians India. 2010;58:608-11.
Howard DH, Meltzer D, Kollman C, Maiers M, Logan B, Gragert L, et al. Use of cost-effectiveness analysis to determine inventory size for a national cord blood bank. Med Decis Making. 2008;28(2):243-53.
Zheng CC, Zhu XY, Tang BL, Zhang XH, Zhang L, Geng LQ, et al. Double vs. single cord blood transplantation in adolescent and adult hematological malignancies with heavier body weight (>/=50 kg). Hematology. 2018;23(2):96-104.
Scaradavou A. Cord blood beyond transplantation: can we use the experience to advance all cell therapies? Br J Haematol. 2021;194(1):14-27.
Ferreira MSV, Mousavi SH. Nanofiber technology in the ex vivo expansion of cord blood-derived hematopoietic stem cells. Nanomedicine. 2018;14(5):1707-18.
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339-48.
Song EY, Huh JY, Kim SY, Kim TG, Oh S, Yoon JH, et al. Estimation of size of cord blood inventory based on high-resolution typing of HLAs. Bone Marrow Transplant. 2014;49(7):977-9.
Shi CY, Wei W, Lyu LJ, Wang Q. Umbilical cord blood application analysis of Guangdong Cord Blood Bank. Chin Med J (Engl). 2020;133(16):1997-8.
Cheng L, Shi C, Wang X, Li Q, Wan Q, Yan Z, et al. Chinese biobanks: present and future. Genet Res (Camb). 2013;95(6):157-64.
Zhaolin Gao YH, Fei Yao and Ziyu Zhou. Public awareness and attitudes toward biobank and sample donation: A regional Chinese survey. Front Public Health. 2022.
Jiajv Chen JH, and Xuekai Xie. Legal and Ethical Challenges in the Construction of China's Biobanks. Biotechnology Law Report. 2021;40(5).
Zhang Y, Li Q, Wang X, Zhou X. China Biobanking. Adv Exp Med Biol. 2015;864:125-40.
Vaught J. Biobanking in China. Biopreserv Biobank. 2015;13(1):1.
Lee S, Jung PE, Lee Y. Publicly-funded biobanks and networks in East Asia. Springerplus. 2016;5(1):1080.
Omae Y, Goto YI, Tokunaga K. National Center Biobank Network. Hum Genome Var. 2022;9(1):38.
Barini R, Ferraz UC, Acacio GL, Machado IN. Does the time between collecting and processing umbilical cord blood samples affect the quality of the sample? Einstein (Sao Paulo). 2011;9(2):207-11.
Lee YH. Clinical utilization of cord blood over human health: experience of stem cell transplantation and cell therapy using cord blood in Korea. Korean J Pediatr. 2014;57(3):110-6.
Minako Iida AD, Mafruha Akter, Alok Srivastava, Joon Ho Moon, Phu Chi Dung, Marjorie Rose Bravo, Aya Aya Gyi, Devinda Jayathilake, Kaiyan Liu, Bor-Sheng Ko, Amir Hamidieh, Kim Wah Ho, Aloysius Ho, Artit Ungkanont, Tasneem Farzana, Joycelyn Sim, Bishesh Poudyal, Khishigjargal Batshkh, Shinichiro Okamoto, Yoshiko Atsuta, Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group(APBMT). The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region. Blood Cell Therapy. 2021;4(2):9.
Rebulla P, Querol S, Pupella S, Prati D, Delgadillo J, De Angelis V. Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain. Front Cell Dev Biol. 2021;9:812038.
Strong A, Gracner T, Chen P, Kapinos K. On the Value of the Umbilical Cord Blood Supply. Value Health. 2018;21(9):1077-82.
Suen SS, Lao TT, Chan OK, Kou TK, Chan SC, Kim JH, et al. Maternal understanding of commercial cord blood storage for their offspring - a survey among pregnant women in Hong Kong. Acta Obstet Gynecol Scand. 2011;90(9):1005-9.
Lu H, Chen Y, Lan Q, Liao H, Wu J, Xiao H, et al. Factors That Influence a Mother's Willingness to Preserve Umbilical Cord Blood: A Survey of 5120 Chinese Mothers. PLoS One. 2015;10(12):e0144001.
Peberdy L, Young J, Massey DL, Kearney L. Parents' knowledge, awareness and attitudes of cord blood donation and banking options: an integrative review. BMC Pregnancy Childbirth. 2018;18(1):395.
Pisula A, Sienicka A, Stachyra K, Kacperczyk-Bartnik J, Bartnik P, Dobrowolska-Redo A, et al. Women's attitude towards umbilical cord blood banking in Poland. Cell Tissue Bank. 2021;22(4):587-96.
Bhandari R, Lindley A, Bhatla D, Babic A, Mueckl K, Rao R, et al. Awareness of cord blood collection and the impact on banking. Pediatr Blood Cancer. 2017;64(7).
Shearer WT, Lubin BH, Cairo MS, Notarangelo LD, Section On HO, Section On A, et al. Cord Blood Banking for Potential Future Transplantation. Pediatrics. 2017;140(5).
Downloads
Published
Issue
Section
License
Copyright (c) 2022 The copyright to the submitted manuscript is held by the Author, who grants the Journal of Medical Science (JMS) a nonexclusive licence to use, reproduce, and distribute the work, including for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Accepted 2022-12-08
Published 2022-12-30
